We are pleased to announce the election of Steffen Saltofte as the new member of the Medicines for Europe Executive Committee during the recent General Assembly in Brussels.

The General Assembly focused on critical issues such as EU pharmaceutical legislation that delivers on accessibility, affordability and availability of the medicines, removing any barriers and delays, and environmental impact.

Medicines for Europe is the official trade association for the European generic, biosimilar and value-added pharmaceutical industries across Europe. Its vision is to provide sustainable access to high quality medicines for Europe, based on 5 important pillars: patients, quality, value, sustainability and partnership.

In his new role, Steffen will collaborate closely with the members of the Medicines for Europe, its staff, and other stakeholders to promote sustainable innovation in the pan-European pharmaceutical platform and enhance patient access to value- added medicines.

“At Zentiva, we have been dedicated for a number of years in driving value-added medicines. I am delighted to share our exceptional skill and long standing experience as part of the Medicine for Europe membership community for the benefit of people who depend on our products every day. I believe that Zentiva's clear vision and straightforward mission can underpin sustainable healthcare in Europe and can ensure that as many people as possible get access to affordable medicines”, said Steffen Saltofte.

Additionally, we are excited to announce that our Corporate Affairs Manager, Tomas Pala, has been appointed as Vice-Chair of the Generics Market Access Committee (GMAC) of the Medicines for Europe. Tomas is passionate about contributing our significant value and expertise to the generics market and increasing the sustainability of pan-European platform, further solidifying Zentiva’s leadership and commitment in the pharmaceutical industry.